4,206 Shares in CareDx, Inc (NASDAQ:CDNA) Purchased by Headlands Technologies LLC

Headlands Technologies LLC purchased a new stake in shares of CareDx, Inc (NASDAQ:CDNA) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,206 shares of the company’s stock, valued at approximately $50,000.

Several other institutional investors and hedge funds have also bought and sold shares of CDNA. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of CareDx by 23.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,751 shares of the company’s stock valued at $82,000 after acquiring an additional 2,211 shares in the last quarter. Strs Ohio boosted its holdings in CareDx by 9.6% in the third quarter. Strs Ohio now owns 36,500 shares of the company’s stock valued at $255,000 after acquiring an additional 3,200 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in CareDx by 8.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 276,751 shares of the company’s stock valued at $1,937,000 after purchasing an additional 20,480 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in CareDx by 3.0% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,024,503 shares of the company’s stock worth $21,172,000 after purchasing an additional 87,378 shares in the last quarter. Finally, Jacob Asset Management of New York LLC lifted its position in shares of CareDx by 105.4% in the 3rd quarter. Jacob Asset Management of New York LLC now owns 50,260 shares of the company’s stock worth $352,000 after purchasing an additional 25,795 shares during the period.

CareDx Trading Up 18.3 %

Shares of CDNA stock opened at $9.18 on Thursday. The company’s fifty day moving average price is $9.62 and its 200-day moving average price is $9.28. The stock has a market cap of $475.34 million, a PE ratio of -2.59 and a beta of 1.42. CareDx, Inc has a 12 month low of $4.80 and a 12 month high of $12.93.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). The business had revenue of $65.57 million for the quarter, compared to analysts’ expectations of $63.66 million. CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The company’s revenue was down 20.4% on a year-over-year basis. During the same period last year, the business earned ($0.34) earnings per share. On average, sell-side analysts forecast that CareDx, Inc will post -1.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CDNA has been the topic of several research analyst reports. Stephens reiterated an “overweight” rating and set a $15.00 price target on shares of CareDx in a research report on Wednesday, April 17th. Craig Hallum upgraded CareDx from a “hold” rating to a “buy” rating and upped their target price for the stock from $12.00 to $15.00 in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.00.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.